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included in the study, with 308 consenting to receive letrozole and 124 opting not to receive letrozole. The authors did not report the exclusion of any patients. The authors reported the infertility diagnoses of the included groups and the period of time over which the study participants had been trying to conceive.
Study design
The study was a prospective cohort design that was based in a single study centre. Treatment assignment was solely determined by patient choice. The authors did not report any loss to follow-up. The study was not blinded.
Analysis of effectiveness
The analysis of effectiveness appears to have accounted for all patients included in the study (in effect, intention to treat). The primary health outcomes were the number of follicles with a diameter greater than 16 mm, the dose of FSH used per cycle and the clinical pregnancy rates. The authors stated that the two study groups were comparable in terms of their baseline characteristics.
Effectiveness results
The FSH alone group had a significantly higher number of mature follicles greater than 16 mm at the day of hCG administration, (p value not reported).
The pregnancy rates were similar between the two groups, with no statistically significant differences. The cumulative pregnancy rate was 27.6% in the letrozole group and 36.3% in the FSH alone group.
The total dose of FSH used was significantly higher in the FSH alone group, (p<0.0001).
Clinical conclusions
The authors concluded that the inclusion of letrozole may reduce the dose of FSH required but does not necessarily lead to better results in terms of efficacy.
Measure of benefits used in the economic analysis
The number of pregnancies was used as the measure of health benefits in the economic analysis.
Direct costs
The study incorporated only the costs of letrozole and FSH. These may be viewed as hospital costs. The cost of FSH was obtained from the Canadian Formulary, while the cost of letrozole was based on an author's assumption. Although discounting was not undertaken, it might not have been relevant since it was unclear if the treatment period was less than 1 year.
